Earnings ·
Acumen Pharmaceuticals reports $78.6M cash balance and expects ALTITUDE-AD Phase 2 topline results in November
ABOSAcumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals reported financial results for the third quarter ended September 30, 2026. The company held $78.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, a decrease from $110.2 million at June 30, 2026. Research and development expenses were $21.1 million for the quarter, compared to $22.0 million in the prior year period. The company expects to report topline results from its ALTITUDE-AD Phase 2 study investigating sabirnetug for early Alzheimer's disease in November 2026. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease.